Serum matrix metalloproteinase-3 in rheumatoid arthritis patients: Correlation with disease activity and joint destruction
Serum matrix metalloproteinase-3 in rheumatoid arthritis patients: Correlation with disease activity and joint destruction
复制标题
DOI：
10.1016/j.ejr.2016.01.001
复制
发表时间：
2016-07-01
影响因子：
0.9
通讯作者：
Gamal, Mohamad
中科院分区：
文献类型：
--
作者：
Fadda, Samia;Abolkheir, Enas;Gamal, Mohamad
本研究旨在检测类风湿关节炎(RA)患者血清基质金属蛋白酶-3(MMP3)水平及其与功能状态、疾病活动度和关节损害的关系。患者和方法：50例符合2010年ACR/EULAR分类标准的RA患者和20例正常对照。按改良健康评估问卷(MHAQ)评定功能障碍。采用28个关节疾病活动度评分(DAS28)和疼痛视觉模拟评分(VAS)进行评定。采用Van der Heijde改良夏普评分(VdHSS)评价放射学关节损伤。结果：RA患者平均年龄46.36±13.63岁，病程5.6±4.75年。血清MMP3水平显著高于对照组(分别为46.78±46.99vs1.98±1.71 ng/ml，p=0.0001)，且与血沉呈显著正相关(p=0.001)，在C反应蛋白、类风湿因子和抗环瓜氨酸肽阳性的患者中显著升高(p=0.0001，p=0.009，p=0.042)。MMP3与DAS28(p=0.0001)、VDHSS(r=0.78，p=0.0001)呈正相关，有糜烂者与无糜烂者比较有显著差异(p=0.001)。血清MMP3水平与累积类固醇剂量呈显著负相关(r=-0.2p=0.03)，且在从未接受抗风湿药物治疗的患者中显著升高(p=0.001)。MMP3与年龄、MHAQ、疼痛VAS无明显相关性。结论：血清MMP3是反映RA患者疾病活动性和关节损害的一种可测量的、有用的特异性标志物。(C)2016年埃及风湿病学会。爱思唯尔B.V.提供的出版服务。这是CC BY-NC-ND许可证(http://creativecommons.org/licenses/by-nc-nd/4.0/).下的一篇开放获取文章
Aim of the work: This study was designed to measure the serum level of matrix metalloproteinase-3 (MMP-3) in rheumatoid arthritis (RA) patients and its correlation with functional status, disease activity and joint damage.Patients and methods: The study included 50 RA patients satisfying 2010 ACR/EULAR classification criteria recruited from Bani-Suef University Hospital and 20 controls. Functional disability was assessed according to Modified Health Assessment Questionnaire (MHAQ). Disease activity score in 28-joints (DAS28) and visual analogue scale (VAS) of pain were evaluated. Radiological joint damage was assessed by Van der Heijde-modified Sharp Score (vdHSS). Serum levels of MMP-3 were measured for all subjects.Results: RA patients (44 females and 6 males) had a mean age of 46.36 +/- 13.63 years and disease duration of 5.6 +/- 4.75 years. Serum MMP-3 levels were higher in patients than in controls (46.78 +/- 46.99 versus 1.98 +/- 1.71 ng/ml respectively, p = 0.0001) and significantly correlated with erythrocyte sedimentation rate (p = 0.001) and were significantly higher in patients with positive C-reactive protein, rheumatoid factor and anti-cyclic citrullinated peptide (p = 0.0001, p = 0.009, p = 0.042, respectively). MMP-3 significantly correlated with DAS28 (p = 0.0001) and vdHSS (r = 0.78, p = 0.0001) and a significant difference was shown in those with erosions compared to those without (p = 0.001). Serum MMP-3 levels significantly correlated negatively with cumulative steroid dose (r = -0.2, p = 0.03) and were significantly higher in patients who never received disease-modifying antirheumatic drugs (p = 0.001). There were no significant relations of MMP-3 with age, MHAQ, VAS for pain.Conclusion: These results indicate that serum MMP-3 is a measurable, useful specific marker of disease activity and joint damage in RA patients. (C) 2016 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).